Experience
Vance Street Capital Partners With System Seals
December 9, 2024
Cooley advised Vance Street Capital, a Los Angeles-based middle-market private equity firm that invests in highly engineered solutions businesses across the industrial technology, medical, life sciences, aerospace and defense sectors, on its acquisition of System Seals, a designer and manufacturer of custom fluid seals for various industrial applications.
Related contacts
Related Practices & Industries
Avid Bioservices Announces $1.1 Billion Acquisition by GHO Capital Partners and Ampersand Capital Partners
November 6, 2024
Cooley advised Avid Bioservices (Nasdaq: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, on its definitive merger agreement to be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion.
Related contacts
Related Practices & Industries
BioAge Labs Announces $198 Million IPO
September 27, 2024
Cooley advised the underwriters of BioAge Labs, a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases, on its $198 million initial public offering.
Related contacts
Related Practices & Industries
Transact Campus Announces $1.6 Billion Sale to Roper Technologies
August 15, 2024
Cooley advised Reverence Capital Partners’ portfolio company Transact Campus, an innovative campus technology and payment solutions company, on a definitive agreement signed by Reverence Capital Partners to sell Transact to Roper Technologies for $1.6 billion.
Related contacts
Related Practices & Industries
Nerio Therapeutics Sells to Boehringer Ingelheim for up to $1.3 Billion
July 29, 2024
Cooley advised Nerio Therapeutics, a drug discovery and development company focused on phosphatases, a notoriously difficult class of potentially high-value therapeutic protein targets, on its sale to Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, for up to $1.3 billion.
Related contacts
Related Practices & Industries
Admissions and credentials
California
New York